Skip to main content
. Author manuscript; available in PMC: 2021 Aug 27.
Published in final edited form as: Vaccine. 2020 Jul 24;38(38):5997–6006. doi: 10.1016/j.vaccine.2020.07.017

Table 1.

Number of Participants Selected by Study and Dosing Group*

Costa Rica HPV-16/18 Vaccine Trial (CVT) India HPV-6/11/16/18 Trial (INDIA)
Dosing Group** Study Entry Month 12/18 Timepoint -N (Median Months of Follow-Up) Month 24/36 Timepoint -N (Median Months of Follow-Up) Study Entry Month 12/18 Timepoint -N (Median Months of Follow-Up) Month 24/36 Timepoint -N (Median Months of Follow-Up)
Single Dose Group 0 30 (14.0) 60 (35.0) 0 40 (21.0) 40 (27.0)
Reduced Dose Group 0 30 (16.0) 60 (35.0) 0 40 (21.5) 40 (28.0)
Full Dose Group 0 30 (12.0) 60 (33.0) 0 40 (20.0) 40 (34.0)
Pre-vaccination Group 10 0 0 10 0 0
*

Due to sample volume limitations, not all samples selected were tested by all assays. Proportion tested for each assay are listed in the text and summarized further in Supplementary Table S1.

**

Single dose group = samples from individuals who received 1-dose; Reduced dose group = samples from individuals who received 2 doses over one or two months; Full dose group = samples from individuals who received either 2 or 3 doses over six months.